Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from MV4-11 cells after treatment with ATRA, NVP-BEZ235 or the combination of both drugs for 3h, 12h and 24h

ABSTRACT: Aberrant activity of the PI3K/AKT/mTOR (PAM) pathway as well as suppressed retinoic acid signaling contribute to enhanced proliferation and a block in differentiation of immature myeloid cells in AML Therefore, we sought to target MV4-11 cells by a combined strategy using small molecule inhibitors against members of the PAM signaling pathway in conjunction with all-trans retinoic acid (ATRA). A detailed analysis of transcriptome changes in MV4-11 cells revealed that NVP-BEZ235 and ATRA regulated the same biologic pathways, but acted on different gene sets within these pathways. Especially, we found a strong repression of MYC-target genes and genes involved in cellular programs such as cell cycle regulation, metabolism or differentiation.

ORGANISM(S): Homo sapiens

PROVIDER: GSE160964 | GEO | 2022/04/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA seq NVP-BEZ235 treatment of U87MG cells

Project description:Glioblastoma (GBM) is the most lethal primary brain cancer that lacks effective molecular targeted therapies. PI3K/AKT/mTOR signaling pathway is activated in 90% of all Glioblastoma Multiforme (GBM) tumors. To gain insight into the impact of the PI3K Pathway on GBM metabolism, we treated U87MG GBM cells with 50nM NVP-BEZ235 (PI3K and mTOR a dual inhibitor) for four days and identified differentially expressed genes with RNA-seq analysis.

2021-12-01 | GSE179667 | GEO

Expression data from MV4-11 cells after treatment with ATRA, NVP-BEZ235 or the combination of both drugs for 3h, 12h and 24h

Project description:Expression data from MV4-11 cells after treatment with ATRA, NVP-BEZ235 or the combination of both drugs for 3h, 12h and 24h

| PRJNA675006 | ENA

RNA seq NVP-BEZ235 treatment of U87MG cells

Project description:RNA seq NVP-BEZ235 treatment of U87MG cells

| PRJNA744516 | ENA

Effect of a dual specificity PI3K/mTOR inhibitor, NVP-BEZ235, on human ovarian cancer cell lines grown in 3D culture

Project description:Analysis of the effects of a dual specificity PI3K/mTOR inhibitor on two human ovarian cell lines, OV2008 and MCAS. Results provide insight into the adaptive response to PI3K/mTOR inhibition in matrix attached ovarian cancer cells. The PI3K/mTOR-pathway is the most commonly deregulated pathway in epithelial cancers and thus represents an important target for cancer therapeutics. Here we show that dual inhibition of PI3K/mTOR in ovarian cancer 3D-spheroids leads to death of the inner matrix-deprived cells, whereas matrix-attached cells are resistant. Resistance is associated with up-regulation of a cellular survival program that involves both FOXO-regulated transcription and a novel translational resistance mechanism resulting in specific up-regulation of IRES-mediated, cap-independent translation. Inhibition of any of several up-regulated proteins, including Bcl-2, EGFR, or IGF1R, abrogates resistance to dual PI3K/mTOR inhibition. These results demonstrate that acute adaptive response to PI3K/mTOR inhibition resembles well-conserved adaptive response to nutrient and growth factor deprivation and how development of rational drug combinations can bypass resistance mechanisms. Total RNA was isolated 6h and 24h after treatment with 1 M-NM-<M NVP-BEZ235 or DMSO vehicle control from 3D grown structures

2012-03-13 | E-GEOD-28992 | biostudies-arrayexpress

NVP-BHG712 alleviates ovariectomy-induced osteoporosis by modulating osteoclastogenesis

Project description:To investigate the effect of NVP-BHG712 on osteoclast differentiation, BMMs were removed from femorae of C57BL/6 mice and treated with NVP-BHG712 for RNA-seq

2024-12-01 | GSE261350 | GEO

Transcriptome profiles of BEZ235 treated Ewing Sarcoma cells

Project description:Transcriptome profiles of BEZ235 treated Ewing Sarcoma cells

2025-09-27 | GSE214256 | GEO

Gene expression and alternative splicing profiles of BEZ235 treated Ewing Sarcoma cells

Project description:TC71 cells treated either with BEZ235 or DMSO

2018-02-14 | GSE93579 | GEO

Influence of BEZ235 and MYC on gene expression in SW620 cells

Project description:SW620 were transfected with siMYC or siCTR at time point 0h. 24h later cells were splitter 1:2, additional 24 h later (48h after transfection) cells were treated with BEZ235 (200nM) or DMSO. Cells were harvested after additional 24h (72h after siRNA transfection; 24h BEZ235 treatment.

2015-08-27 | E-MTAB-2882 | biostudies-arrayexpress

Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma.

Project description:Capicua–double homeobox 4 (CIC-DUX4) rearranged sarcomas (CDSs) are extremely rare, highly aggressive primary sarcomas that represent a major therapeutic challenge. To identify selective therapeutic targets of CDS, we performed RNA sequencing of primary tumor samples from patients, patient-derived xenografts (PDXs) and PDX-derived cell lines and we highlighted an HMGA2/IGF2BPs/IGF2/IGF1R/AKT-mTOR axis that characterizes CDS. This highly active axis confers to CDSs sensitivity to both trabectedin, which prevents HMGA proteins from binding to IGF2BP2/3 promoters, and PI3K/mTOR inhibitor NVP-BEZ235 (dactolisib). Combined treatments with trabectedin and NVP-BEZ235 completely abolish the activation of the IGF2/IGF1R/AKT/mTOR axis and the in vivo growth of CDS tumors. The development of representative PDXs and PDX-derived cell lines models has helped to identify the unique sensitivities of CDS towards AKT/mTOR inhibitors and trabectedin, revealing a mechanism-based therapeutic strategy to fight this lethal cancer.

2022-01-12 | GSE165032 | GEO